EMA Gives Nod To Bydureon, Approves Additional Indication For Pradaxa
This article was originally published in The Pink Sheet Daily
Executive Summary
The CHMP has recommended Bydureon for authorization, despite reservations having been expressed by FDA. An additional indication for Pradaxa was also recommended, boosting the drug's profile as a potential blockbuster.
You may also be interested in...
German Reimbursement Assessment Process Fells Third Rx Victim
Lilly/Boehringer's Trajenta will not be marketed in Germany, as companies feel it will not meet the criteria set by authorities to get the reimbursement level it deserves.
German Reimbursement Assessment Process Fells Third Rx Victim
Lilly/Boehringer's Trajenta will not be marketed in Germany, as companies feel it will not meet the criteria set by authorities to get the reimbursement level it deserves.
In Seeking Focus, Ipsen Turns To Specialty Pharma Model
Marc de Garidel, Ipsen’s new CEO, is re-focusing the mid-sized French group’s attention on its core commercial assets, trimming the portfolio, and narrowing down early-stage R&D. The de-risking move turns Ipsen sharply in a specialty pharma direction that may please some investors over the near-term, but which raises questions related to the future viability of Ipsen’s R&D engine.